The type dimension of the Bone Density Scanner market is divided into four principal sub‑categories: Dual‑energy X‑ray absorptiometry (DXA), Quantitative Computed Tomography (QCT), Ultrasound‑based devices, and Peripheral scanners. DXA remains the dominant technology, accounting for roughly 60 % of total revenue because of its established clinical validation, high precision, and widespread reimbursement. QCT, representing about 15 % of the market, offers three‑dimensional volumetric analysis that is valuable for complex cases, albeit at higher cost and radiation exposure. Ultrasound devices, contributing close to 12 % of sales, are favored in primary‑care and point‑of‑care settings due to their portability and radiation‑free operation, though they provide lower diagnostic certainty. Peripheral scanners—hand‑ or heel‑focused units—capture the remaining 13 % and serve niche markets such as osteoporosis screening in community health programs. Each type’s revenue share reflects its clinical utility, cost structure, and adoption rate, collectively shaping the overall market size.